Malignant Ascites Ascites Fluid Analysis: Mandatory Tests
Total Page:16
File Type:pdf, Size:1020Kb
Approach to Ascites Paul Martin MD, FRCP,FRCPI Division of Hepatology, University of Miami. • 62 year old man referred with abdominal distension. • Remote icteric illness during college • Describes himself as social drinker • P/E mild muscle wasting, BP 110/70, Pulse 90/minute, afebrile • Mild flank distension, diminished liver span with splenic dullness ? Shifting dullness, no fluid wave • Initial Labs: Bilirubin 1.9 mgs/dl, AST 70, ALT 23, alk phos 135, platelet count 110 k, INR 1.2 • Ultrasound perfomed ULTRASOUND IS THE MOST SENSITIVE METHOD TO DETECT ASCITES Ultrasound is the Most Sensitive Method to Detect Ascites Ascites Liver Ascites Initial workup DIAGNOSTIC PARACENTESIS Diagnostic Paracentesis Indications New-onset ascites Admission to hospital Symptoms/signs of SBP Renal dysfunction Unexplained encephalopathy Contraindication s None INITIAL WORKUP OF ASCITES: DIAGNOSIS PARACENTESIS Initial Workup of Ascites Diagnostic Paracentesis Optional Glucose, LDH Amylase Protein/Albumin Routine ? secondary ? infection cirrhotic ? pancreatic ascites PMN count ascites Cytology Culture ? SBP ? malignant ascites Ascites Fluid Analysis: Mandatory Tests • Cell count – WBC & RBC – Purple top tube • Serum albumin - ascites albumin gradient (SAAG) – Terms exudate & transudate – Should no longer be used – Apply to only pleural effusions • Cultures – 10-20 ml in blood culture bottles ASCITES CAN BE CHARACTERIZED BY SERUM-ASCITES ALBUMIN GRADIENT (SAAG) AND ASCITES PROTEIN Ascites Can Be Characterized by Serum- Ascites Albumin Gradient (SAAG) and Ascites Protein Source of ascites Hepatic sinusoids Peritoneum SAAG > 1.1 SAAG < 1.1 “Capillarized” sinusoid Normal “leaky” sinusoid Peritoneal lymph Ascites protein < 2.5 Ascites protein > 2.5 Ascites protein > 2.5 Sinusoidal Post-sinusoidal Peritoneal pathology hypertension hypertension - Malignancy -Cirrhosis - Cardiac ascites - Tuberculosis -Late Budd- - Early Budd-Chiari Chiari - Veno-occlusive disease Etiology of Ascites TB Other Malignancy CHF Cirrhosis 5% Mixed Ascites Fluid Analysis: Optional Tests • Infected ascites – Total protein, LDH & glucose – Gram stain – To R/O free perforation of the gut – Not for SBP (10% sensitive) • Milky ascites – TG > 200 mg/ml – Occasionally high WBC count • Malignant ascites – LDH (ascites > serum) – Cytology Ascites Classification: High Gradients • Serum albumin - ascites albumin (SAAG) > 1.1 • Portal hypertension present (90-95%) • Causes – Liver – Cirrhosis – Very severe, acute hepatitis – Cancer: massive liver mets – Venous – Budd-Chiari syndrome – Veno-occlusive disease – Portal vein thrombosis – Cardiac (R-CHF, constrictive pericarditis) Ascites Classification: Low Gradients • Serum albumin - ascites albumin (SAAG) < 1.1 g/dL • Causes (every other organ in the abdomen) – Perforated gastric ulcer – Ruptured gallbladder / biliary leak – Infarcted bowel – Pancreatitis – Renal – Nephrotic syndrome – Ruptured urinary bladder – Peritoneum – Infectious – Cancer • 62 year old man with ascites • Ascites tapped: albumin 1.1 g/dl, wbc < 250,serum albumin 3.1 g/ dl • SAAG: 2 consistent with portal hypertension • HCV antibody positive,: diagnosis cirrhosis • Describes himself as social drinker Ascites Initial management MANAGEMENT OF UNCOMPLICATED ASCITES Management of Uncomplicated Ascites Definition: Ascites responsive to diuretics in the absence of infection and renal dysfunction Sodium restriction Effective in 10-20% of cases Predictors of response: mild or moderate ascites, Urine Na excretion > 50 mEq/day Diuretics Should be spironolactone-based A progressive schedule (spironolactone furosemide) requires fewer dose adjustments than a combined therapy (spironolactone + furosemide) DEFINITION AND TYPES OF REFRACTORY ASCITES Definition and Types of Refractory Ascites Occurs in ~10% of cirrhotic patients Diuretic-intractable ascites 80% Therapeutic doses of diuretics cannot be achieved because of diuretic-induced complications Diuretic-resistant ascites 20% No response to maximal diuretic therapy (400 mg spironolactone + 160 mg furosemide/day) Arroyo et al. Hepatology 1996; 23:164 Ascites Beyond diuretics Ascites: Other Options • Repeated Large Volume Paracentesis: inconvenient, if required < every 2 weeks suggests non-compliance with salt and fluid restriction • TIPS: used to manage ascites, recurrent variceal hemorrhage, hepatic hydrothorax etc. May worsen liver disease TIPS Blood Flow Changes COMPARED TO LVP, TIPS IS ASSOCIATED WITH LESS ASCITES RECURRENCE BUT MORE ENCEPHALOPATHY Compared to LVP, TIPS Reduces Ascites Recurrence But Increases Risk of Encephalopathy LVP TIPS p (n=35) (n=35) Recurrent ascites 11.7± 2.7* 3.6 ± 1.7 0.003 TIPS obstruction - 40% - Grade 3-4 PSE 0.5 ± 0.02 1.1 ± 0.02 0.02 Death 51% 57% ns * Episodes/patient Gines et al., Gastroenterology 2002; 123:1839 Ascites: Other Options • Peritoneovenous shunt: largely replaced by TIPS • Pleurx catheter; left in situ, used in malignant ascites PERITONEO-VENOUS SHUNT (PVS) IS USEFUL IN THE TREATMENT OF REFRACTORY ASCITES Peritoneo-Venous Shunt (PVS) is Useful in the Treatment of Refractory Ascites Use of jugular vein will hinder TIPS placement One-way valve Intraabdominal adhesions may complicate liver transplant surgery Ascites: Survival & OLT 100 80 After Liver Transplant Survival 60 (%) 40 20 1 2 3 4 5 6 Onset Years Cirrhosis Background HISTOLOGICAL IMAGE OF CIRRHOSIS Fibrosis Regenerative nodule PATHOGENESIS OF LIVER FIBROSIS Normal Hepatic SInusoid Retinoid droplets Fenestrae Hepatic stellate cell Space of Disse Sinusoidal endothelial cell Hepatocytes PATHOGENESIS OF LIVER FIBROSIS Alterations in Microvasculature in Cirrhosis Activation of stellate cells Collagen deposition in space of Disse Constriction of sinusoids Defenestration of sinusoids IN CIRRHOSIS, NITRIC OXIDE ACTIVITY IS REDUCED AND THE ACTIVITY OF VASOCONSTRICTORS IS INCREASED In Cirrhosis, Nitric Oxide (NO) Activity is Reduced and Vasoconstrictors (VC) are Increased Cirrhosis Prognosis Stable cirrhosis in absence of complications (Fattovich, Gastroenterology 1997) No complications Complications Platelets <115,000 > predictor Stable Cirrhotic • Routine Health Maintenance • Surveillance for HCC • Screening and prophylaxis of varices • SBP prophylaxis Management of the stable cirrhotic: HCC surveillance • Cirrhosis is high risk factor for HCC: 23 fold risk after 3.5 years (Chalasani, Amer J Gastr 1999) • If presenting with symptoms, median survival is 4 months • Surveillance: – AFP sensitivity 64%/specificity 91% – UTZ sensitivity 59-74%/specificity 94% – Optimal frequency unknown Cirrhosis Complications NATURAL HISTORY OF CIRRHOSIS Development of Complications in Compensated Cirrhosis 100 80 Probability of 60 Ascites Jaundice developing event Encephalopathy 40 GI hemorrhage 20 0 0 20 40 60 80 100 120 140 160 Months Gines et. al., Hepatology 1987; 7:122 SURVIVAL TIMES IN CIRRHOSIS Decompensation Shortens Survival 100 80 Median survival 60 All patients~ 9 years with cirrhosis Probability of survival 40 20 Decompensated Median cirrhosis survival 0 ~ 1.6 years 0 20 40 60 80 100 120 140 160 180 Months Gines et. al., Hepatology 1987;7:122 COMPLICATIONS OF CIRRHOSIS Complications of Cirrhosis Result from Portal Hypertension or Liver Insufficiency Portal hypertension Variceal hemorrhage SBP Ascites Cirrhosis HRS Liver insufficiency Encephalopathy Jaundice Cirrhosis Varices Prevalence and Size of Esophageal Varices in Patients with Newly-Diagnosed Cirrhosis 100 80 Large % 60 Patients with 40 Medium varices 20 Small 0 Overall Child A Child B Child C n=494 n=346 n=114 n=34 Mortality 20%-30% at 6 weeks Pagliaro et al., In: Portal Hypertension: Pathophysiology and Management, 1994: 72 Large Varices are more Likely to Rupture No Varices 100 Small Varices p<0.01 * 75 % Patients 50 Large Varices * * without bleeding 2-year probability of first 25 bleed: Small varices: 7% Large varices: 30% 0 60 0 12 24 36 48 52 Time (months) *Merli et al., Hepatol 2003; 38:266, **Conn et al., Hepatology 1991; 13:902 VARICES INCREASE IN DIAMETER PROGRESSIVELY Varices Increase in Diameter Progressively No varices Small varices Large varices 7-8%/year 7-8%/year Merli et al. J Hepatol 2003;38:266 PROGNOSTIC INDICATORS OF FIRST VARICEAL HEMORRHAGE Variceal hemorrhage Varix with red signs Predictors of hemorrhage: Variceal size Red signs Child B/C NIEC. N Engl J Med 1988; 319:983 TREATMENT OF ACUTE VARICEAL HEMORRHAGE Treatment of Acute Variceal Hemorrhage General Management: IV access and fluid resuscitation Do not overtransfuse (hemoglobin ~ 8 g/dL) Antibiotic prophylaxis Specific therapy: Pharmacological therapy: terlipressin, somatostatin and analogues, vasopressin + nitroglycerin Endoscopic therapy: ligation, sclerotherapy Shunt therapy: TIPS, surgical shunt PROPHYLACTIC ANTIBIOTICS PREVENT EARLY VARICEAL REBLEEDING Probability of Remaining Free of Recurrent Variceal Hemorrhage 1.0 Prophylactic antibiotics (n=59) 0. 8 0. No antibiotics (n=61) % 6 free of 0. variceal 4 hemorrh 0. age 2 0 0 1 2 3 12 18 24 30 Follow-up (months) Hou M-C et al., Hepatology 2004; 39:746 Prophylaxis of Variceal Hemorrhage Diagnosis of Cirrhosis Endoscopy No Varices Small Varices Medium/Large Varices Follow-up EGD in 2-3 years* Follow-up EGD in 1-2 years* *EGD every year in decompensated cirrhosis Beta-blocker therapy No Contraindications •Stepwise increase until maximally tolerated dose Contraindications •Continue beta-blocker (life-long) or Beta-blocker intolerance Endoscopic Variceal Band Ligation CLASSIFICATION OF GASTRIC VARICES Classification of